Comparative biodistribution of potential anti-glioblastoma conjugates [111In]DTPA-HEGF and [111In]Bz-DTPA-hEGF in normal mice

Cancer Biotherapy and Radiopharmaceuticals

Volumn 19, Issue 4, 2004, Pages 491-501

  Tolmachev, Vladimir ^a   Orlova, Anna ^a   Wei, Qichun ^b   Bruskin, Alexander ^a   Carlsson, Jörgen ^a   Gedda, Lars ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

111In Bz DTPA heGF; 111In DTPA IiEGF; Biodistribution; Mice; Tumor targeting

Indexed keywords

AMINO ACID; EPIDERMAL GROWTH FACTOR RECEPTOR; PENTETATE INDIUM IN 111;

ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; CONJUGATE; DRUG DISTRIBUTION; DRUG UPTAKE; FEMALE; GLIOBLASTOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; URINARY EXCRETION;

ANIMALS; EPIDERMAL GROWTH FACTOR; FEMALE; GLIOBLASTOMA; INDIUM RADIOISOTOPES; ISOTHIOCYANATES; MICE; PENTETIC ACID; RADIOPHARMACEUTICALS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 4644325597     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2004.19.491     Document Type: Article

References (49)

1. Lang O, Liebermeister E, Liesegang J, et al. Radiotherapy of glioblastoma multiforme. Feasibility of increased fraction size and shortened overall treatment. Strahlenther Onkol 1998;174:629.
2. Nieder C, Nestle U, Ketter R, et al. Hyperfractionated and accelerated-hyperfractionated radiotherapy for glioblastoma multiforme. Radiat Oncol Investig 1999;7:36.
3. Arista A, Sturiale C, Riva P, et al. Intralesional administration of I-131-labeled monoclonal antibodies in the treatment of malignant gliomas. Acta Neurochir (Wien) 1995;135:159.
4. Riva P, Arista A, Sturiale C, et al. Glioblastoma therapy by direct intralesional administration of 1-131 radioiodine-labeled antitenasein antibodies. Cell Biophys 1994;37:24.
5. 131I-labeled antitenasein monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: Phase I trial results. Clin Cancer Res 1996;2:963.
6. Riva P, Franceschi G, Riva N, et al. Role of nuclear medicine in the treatment of malignant gliomas: The locoregional radioimmunotherapy approach. Eur J Nucl Med 2000;27:601.
7. 131I-labeled antitenasein monoclonal antibody BC-2. Int J Cancer 1992;51:7.
8. Cokgor I, Akabani G, Kuan CT, et al. Phase I trial results of iodine-131-labeled antitenasein monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol 2000;18:3862.
9. 3-S-octreotide (DOTATOC): a pilot study in human gliomas. ClIn Cancer Res 1999;5:1025.
10. 3-octreotide (DOTATOC). Swiss Med Wkly 2001;131: 640.
11. 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: An extended pilot study. Eur J Nucl Med Mol Imaging 2002;29:486.
12. Barker FG 2nd, Simmons ML, Chang SM, et al. EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2001;51:10.
13. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: From concept to clinical diagnosis. J Neuro-oncol 1999;1:44.
14. Huncharek M, Kupelnick B. Epidermal growth-factor receptor gene amplification as a prognostic marker in glioblastoma multiforme: Results of a meta-analysis. Oncol Res 2000;12:107.
15. Watanabe K, Tachibana O, Sata K, et al. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996;6:217.
16. 131I-EGF on cultured human glioma cells. J Neuro-oncol 1990;9:201.
17. Reilly RM, Gariepy J. Factors influencing the sensitivity of tumor imaging with a receptor-binding radiopharmaceutical. J Nucl Med 1998;39:1036.
18. 111In-labeled epidermal growth factor (EGF) bound to cultured A431 tumor cells. Nuc Med Biol 2000;27:827.
19. 111In] Bz-DTPA-hEGF: Preparation and in vitro characterisation of potential anti-glioblastoma targeting peptide. Cancer Biother and Radiopharm 2003;18:643.
20. 90Y. Radiother Oncol 1991;21:91.
21. O'Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 1995;36:1902.
22. Bernhardt P, Forssell-Aronsson E, Jacobsson L, et al. Low-energy electron emitters for targeted radiotherapy of small tumors. Acta Oncol 2001;40:602.
23. de Jong M, Breeman WA, Bernard HF, et al. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogs. Q J Nucl Med 1999;43:356.
24. Krenning EP, de Jong M, Kooij PP, et al. Radiolabeled somatostatin analog(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol 1999;10(Suppl 2):S23.
25. 111In-pentetreotide. State of the art and perspectives Q J Nucl Med 2000;44:88.
26. 111In for imaging human breast cancer. J Nucl Med 2000;41:903.
27. 111In-DTPA-hEGF, chemotherapeutic agents and gamma radiation on EGFR-positive positive breast cancer cells. Nucl Med Biol 2002;29: 693.
28. 111In for imaging human breast cancer. J Nucl Med 2000;41:903.
29. 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts. J Nucl Med 2003;44:1469.
30. Williams MA, Rapoport H. Synthesis of enantiomerically pure diethylenetriaminepenta-acetic acid analogs. L-phenylalanine as the educt for substitution at the central acetic acid. J Org Chem 1993;58:1151.
31. 111In-labeled SCN-bz-DTPA-BC-2 MAb following locoregional injection into glioblastomas. Int J Cancer 1997;71:810.
32. St Hilaire RJ, Hradek GT, Jones AL. Hepatic sequestration and biliary secretion of epidermal growth factor: evidence for a high-capacity uptake system. Proc Natl Acad Sci USA 1983;80:3797.
33. Yanai S, Sugiyama Y, Iga T, et al. Kinetic analysis of the downregulation of epidermal growth factor receptors in rats in vivo. Am J Physiol 1990;258:C593.
34. Wilson JA, Rogers MJ, Hawkins RA, et al. Epidermal growth factor receptors and oestrogen receptors in the head and neck. Clin Otolaryngol 1993;18:66.
35. Nagao K, Hisatomi H, Hirata H, et al. Expression of molecular marker genes in various types of normal tissue: Implication for detection of micrometastases. Int J Mol Med 2002;10:307.
36. McNeil BJ, Rappeport JM, Nathan DG. Indium chloride scintigraphy: An index of severity in patients with aplastic anaemia. Br J Haematol 1976;34:599.
37. 111In chloride bone marrow scintigraphy and ferrokinetic studies in a case of sickle-cell anemia with transient erythroid aplasia. Acta Haematol 1979;61:330.
38. Reilly R, Lee N, Houle S, et al. In vitro stability of EDTA and DTPA immunoconjugates of monoclonal antibody 2G3 labeled with indium-111. [abstr.] Int J Rad Appl Instrum 1992;43:961.
39. Mardirossian G, Wu C, Hnatowich DJ. The stability in liver homogenates of indium-111 and yttrium-90 attached to antibody via two popular chelators. Nucl Med Biol 1993;20:65.
40. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: Present status, future prospects, and limitations. Eur J Nucl Med 1998; 25:201.
41. Arano Y, Fujioka Y, Akizawa H, et al. Chemical design of radiolabeled antibody fragments for low renal radioactivity levels. Cancer Res 1999;59:128.
42. Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTATOC: First clinical results. Eur J Nucl 1999;26:1439.
43. Moll S, Nickeleit V, Mueller-Brand J, et al. A new cause of renal thrombotic microangiopathy: Yttrium 90-DOTATOC internal radiotherapy. Am J Kidney Dis 2001;37:847.
44. Valkema R, De Jong M, Bakker WH, et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: The Rotterdam experience. Semin Nucl Med 2002;32:110.
45. Rolleman EJ, Valkema R, De Jong M, et al. Safe and effective inhibition of renal uptake of radiolabeled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 2003;30:9.
46. Mattes MJ. Biodistribution of antibodies after intraperitoneal or intravenous injection and effect of carbohydrate modifications. J Natl Cancer Inst 1987;79:855.
47. Stein R, Goldenberg DM, Ong GL, et al. Manipulation of blood clearance to optimize delivery of residualizing label-antibody conjugates to tumor cells in vivo. J Nucl Med 1997;38:1392.
48. Patel S, Stein R, Ong GL, et al. Enhancement of tumor-to-nontumor localization ratios by hepatocyte-directed blood clearance of antibodies labeled with certain residualizing radiolabels. J Nucl Med 1999;40:1392.
49. 111In-labeled, biotinylated antibodies to enhance tumor/nontumor localization ratios. Cancer Biother Radiopharm 2002;17:307.